Genting-backed biotech firm completes first assessment of Covid-19 treatment trial
KUALA LUMPUR (Dec 13): Genting Bhd’s biotechnology arm Celularity Inc said its independent data monitoring committee (DMC) had completed the first assessment of an ongoing study of natural killer (NK) cell therapy in adults with Covid-19 and that the observed clinical findings justify the continuation of the trial of the potential therapeutic treatment for Covid-19 patients with limited treatment options. In its latest statement on Dec 1, US-based Celularity said the Phase I/II CYNK-001-Covid-19 clinical trial is continuing to enroll to the next evaluation milestone where the external, ind...
Source: theedgemarkets.com